Benefits and risks assessment of simvastatin in familial hypercholesterolaemia

Expert Opinion on Drug Safety

Volumn 4, Issue 2, 2005, Pages 171-181

  Alonso, Rodrigo ^a   Mata, Nelva ^b   Mata, Pedro ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

Author keywords

Atherosclerotic disease; Hypercholesterolaemia; Low density lipoprotein cholesterol (LDL C); Simvastatin

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; CERIVASTATIN; CYTOCHROME P450 3A4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; SIMVASTATIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; GASTROINTESTINAL TOXICITY; GENETIC ANALYSIS; HEADACHE; HEART PROTECTION; HEREDITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPOLIPEMIA; LIPID OXIDATION; LIVER METABOLISM; LIVER TOXICITY; LONG TERM CARE; MYALGIA; MYOPATHY; PLEIOTROPY; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; SLEEP DISORDER; SOCIOECONOMICS;

AGE OF ONSET; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; COMORBIDITY; CORONARY DISEASE; DRUG COSTS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK ASSESSMENT; SIMVASTATIN;

EID: 20944432939     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.2.171     Document Type: Review

References (95)

1. GOLDSTEIN JL, HOBBS HH, BROWN MS: Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Eds. The metabolic and molecular basis of inherited diseases. Nueva York: McGraw-Hill (2001) 120:2863-2913
2. HEATH K, GAHAN M, WHITTALL R, HUMPHRIES S: Low-density lipoprotein receptor gene (LDL-R) world-wide website in familial hypercholesterolemia: update, new features and mutations analysis. Atherosclerosis (2001) 154:243-246
3. INTERNATIONAL PANEL ON MANAGEMENT OF FAMILIAL HYPERCHOLESTEROLEMIA: Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis (2004) 173:55-68.
4. SCIENTIFIC STEERING COMMITTEE on behalf of the Simon Broome register: Risk of fatal coronary heart disease in familial hypercholesterolemia. Br. Med. J. (1991) 303:893-896.
5. MABUCHI H, KOIZUMI J, SHIMIZU M, TAKEDA R: Development of coronary heart disease in familial hypercholesterolemia. Circulation (1989) 79:225-232.
6. MATA P, ALONSO R, CASTILLO S, POCOVI M: MedPed and the Spanish familial hypercholesterolemia foundation. Atherosclerosis (2002) (suppl.2):9-11
7. ALONSO R, CASTILLO S, CIVEIRA F et al.: Heterozygous familial hypercholesterolemia in Spain. Description of 819 non related cases. Med. Clin. (Barc) (2002) 118:487-492.
8. TYBJAERG-HANSEN A, HUMPHRIES SE: Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature cardiovascular disease. Atherosclerosis (1992) 96:91-107.
9. KOTZE MJ, PEETERS AV, LANGENHOVEN E et al.: Phenotypic expression and frequency of familial defective apolipoprotein B 100 in Belgian hypercholesterolemics. Atherosclerosis (1994) 111:217-225
10. VARRET M, RABES JP, SAINT-JORE B et al.: A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am. J. Hum. Genet. (1999) 64:1378-1387
11. BERGE KE, TIAN H, GRAF CA et al.: Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science (2000) 290:1771-1775
12. ZULIANI G, ARCA M, SIGNORE A et al.: Characterization of a new form of inherited hypercholesterolemia: familial recessive hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. (1999) 19:802-809.
13. PULLINGER C, ENG C, SALEN G et al.: Human cholesterol 7α-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J. Clin. Invest. (2002) 110:109-117.
14. CELERMAJER DS, SORENSEN KW, GOOCH VM et al.: Non invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet (1992) 340:1111-1115.
15. SANPIETRO T, TUONI M, FERDEGHINI M et al.: Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. Circulation (1997) 96:1381-1385
16. ALONSO R, MATA P, DE ANDRES R et al.: Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin. Atherosclerosis (2001) 157:423-429.
17. TAMAI O, MATSUOKA H, ITABE H et al.: Single LDL-apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation (1997) 95:76-82.
18. KANE JP, MALLOY MJ, PORTS TA et al.: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimes. JAMA (1990) 264:3007-3012
19. THOMPSON GR, MAHER VMG, MATTHEWS S et al.: Familial Hypercholesteorlemia regression study: A randomised trial of low density lipoprotein apheresis. Lancet (1995) 345:811-816
20. EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). JAMA (2001) 285:2486-2495.
21. STEIN E, STENDER S, MATA P et al.: Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am. Heart J. (2004) 148:447-455.
22. RAUCH U, OSENDE JI, CHESEBRO JH et al.: Statins and Cardiovascular diseases: multiple effects of lipid-lowering therapy by statins. Atherosclerosis (2000) 153:181-189
23. NO AUTHORS: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383-1389.
24. SHEPHERD J, COBBE S, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (WOSCOPS). N. Engl. J. Med. (1995) 333:1301-1307
25. SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events in patients with average cholesterol levels (CARE). N. Engl. J. Med. (1996) 335:1001-1009.
26. DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels (AFCAPS/TexCAPS). JAMA (1998) 279:1615-1622.
27. THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHEMIC DISEASE (LIPID) STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cohlesterol levels. N. Engl. J. Med. (1998) 339:1349-1357
28. HEART PROTECTIVE STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo-controlled trial. Lancet (2002) 360:7-22
29. SCIENTIFIC STEERING COMMITTEE on behalf of the Simon Broome Register Group: Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis (1999) 142:105-112.
30. KNOPS RE, KROON AA, MOL MJ et al.: Long-term experience (6 years) with simvastatin in patients with heterozygous familial hypercholesterolemia. Neth. J. Med. (1995) 46:171-178.
31. OSE L, KASTELEIN J, SCOTT R et al.: Efficacy and six-month safety of simvastatin 80 mg/day: Results from the worldwide simvastatin expanded dose program (WSEDP). Nutr. Metab. Cardiovasc. Dis. (1998) 8:135-143
32. DE SAUVAGE NOLTING P, BURIMA R, HUTTEN B et al.:: Two-year effciacy and safety of simvastatin 80 mg in familial hypercholesterolemia (The examination of probands and relatives in statin studies with familial hypercholesterolemia [ExPRESS FH]). Am. J. Cardiol. (2002) 90:181-184
33. MATA P, ALONSO R, BADIMON JJ: Benefits and risks of simvastatin in patients with familial hypercholesterolemia. Drug Saf. (2003) 26:769-786.
34. TODD PA, GOA KL: Simvastatin: a review of its pharmacological properties and therapeutic potential in hypercholesterolemia. Drugs (1990) 40:583-607.
35. PLOSKER G, MCTAVISH D: Simvastatin: A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolemia. Drugs (1995) 50:334-363
36. MAURO VF: Clinical pharmacokinets and practical applications of simvastatin. Clin. Pharmacokinet. (1993) 24:195-202.
37. CHENG H, ROGERS JD, SWEANY AE et al.: Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzime A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm. Res. (1992) 9:1629-1633
38. GRUER P, VEGA JM, MERCURI M et al.: Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am. J. Cardiol. (1998) 84:811-815.
39. PEDERSEN TR, WILHELMSEN L, FAERGEMAN O et al.: Follow-up study of patients randomised in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am. J. Cardiol. (2000) 86:257-262.
40. STRANDBERG PE, PYORALA K, COOK TJ et al.: Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet (2004) 364:771-777.
41. RAAL FJ, PILCHER GJ, ILLINGWORTH DR et al.: Expanded-dose simvastatin is effective in homozygous familial hypercholesterolemia. Atherosclerosis (1997) 135:249-256.
42. RAAL FJ, PILCHER GJ, VELLER M et al.: Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventig the progression of atherosclerosis in homozygous familial hypercholesterolemia - a direct measurement with ultrasound imaging. Am. J. Cardiol. (1999) 84:1344-1346.
43. MOL MJ, ERKELENS DW, GEVERS LEUVEN JA et al.: Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolemia. Lancet (1986) 8513:936-939.
44. MOL MJ, ERKELENS DW, GEVERS LEUVEN JA et al.: Simvatatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolemia. Atherosclerosis (1988) 69:131-137.
45. HAGEMENAS FC, PAPPU AS, ILLINGWORTH DR.: The effect of simvastatin on plasma liporptoeins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolemia. Eur. J. Clin. Invest. (1990) 20:150-157.
46. DE SAUVAGE NOLTING P, BURIMA R, HUTTEN B et al.: Baseline lipid values partly determine the response to high dose simvastatin in patients with familial hypercholesterolemia. The examination of probands and relatives in statin studies with familial hypercholesterolemia [ExPRESS FH] Atherosclerosis (2002) 164:347-354.
47. ILLINGWORTH DR, BACON S, PAPPU A et al.: Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis (1992) 96:53-64.
48. WIERZBICKI AS, LUMB PJ, SEMRA Y, CHIK G, CHRIST ER, CROOK MA: Atorvastatin compared with simvastatin-based therapies in the management of severe familial hypercholesterolemias. QJ Med. (1999) 92:387-394.
49. WIERZBICKI AS, LUMB PJ, SEMRA YK, CROOK MA: High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolemia. QJ Med. (1998) 91:291-294.
50. WIERZBICKI AS, LUMB PJ, CHIK G, CROOK MA: Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolemia. Int. J. Clin. Pract. (1999) 53:609-611
51. STEIN EA, ILLINGWORTH DR, KWITEROVICH PO et al.: Efficacy and safety of lovastatin in adolescents males with heterozygous familial hypercholesterolemia: a randomised controlled trial. JAMA (1999) 281:137-144.
52. WIEGMAN A, HUTTEN BA, DE GROOT E et al.: Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA (2004) 292:331-337.
53. CROWFORD ML: From the Food and Drug Administration. JAMA (2002) 287:1640.
54. STEIN EA: Treatment of familial hypercholesterolemia with drugs in children. Arteriosclerosis (1989) 9(suppl. 1):I145-I151.
55. DUCOBU J, BRASSEUR D, CHAUDRON S et al.: Simvastatin use in children (Letter). Lancet (1992) 339:1488.
56. STEFANUTTI C, LUCANI G, VIVENZIO A, DI GIACOMO S: Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood. Drug Exptl. Clin. Res. (1999) 25:23-28.
57. DIRISAMER A, HACHEMIAN N, BUCEK Ra, WOLF F, REITER M, WIDHALM K: The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation. Eur. J. Pediatr. (2003) 162:421-425.
58. DE JONGH S, OSE L, SZAMOSI T et al.: Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a ranomized, double-blind, placebo-controlled trial with simvastatin. Circulation (2002) 106:2231-2237.
59. DE JONGH S, LILIEN MR, OP'T ROODT J, STROES ES, BAKKER HD, KASTELEIN JJ: Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J. Am. Coll. Cardiol. (2002) 40:2117-2121.
60. SIJBRANDS E, LOMBARDI MP, WESTENDORP R et al.: Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations. Atherosclerosis (1998) 139:247-253
61. HEATH K, GUDNASON V, HUMPHRIES SE et al.: The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis (1999) 143:41-54.
62. CHAVES FJ, REAL JT, GARCIA-GARCIA AB et al.: Genetic diagnosis of familial hypercholesterolemia in a South European outbread population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and High-density lipoprotein cholestero. J. Clin. Endocrinol. Metab. (2001) 86:4926-4932.
63. VOHL MC, SZOTS F, LELIEVRE M et al.: Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Atherosclerosis (2002) 160:361-368.
64. COUTURE P, BRUN LD, SZOTS et al.: Association of specific LDL receptor-gene mutations with differential plasma liporprotein response to simvastatin in young French-Canadians with heterozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. (1998) 18:1007-1012.
65. CASTILLO S, REYES G, TEJEDOR D et al.: A double mutant (N543H+2393del9) allele in the LDL receptor gene in familial hypercholesterolemia: effect on plasma cholesterol levels and cardiovascular disease. Hum. Mutat. (2002) (online)
66. BRENSIKE JF, LEVY RI, KELSEY SF et al.: Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II coronary intervention study. Circulation (1984) 69:313-324.
67. KROON AA, AENGEVAEREN W, VAN DER WERF T et al.: LDL-Apheresis atherosclerosis regression study (LAARS). Effect of agressive versus conventional lowering treatment on coronary atherosclerosis. Circulation (1996) 93:1826-1835.
68. KROON A, VAN ASTEN W, STALENHOEF A: Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercohlesterolemic patients with coronary artery disease. Ann. Intern. Med. (1996) 125:945-954.
69. SMILDE TJ, WISSEN S, WOLLERSHEIM H et al.: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet (2001) 357:577-581.
70. DE SAUVAGE NOLTING P, DE GROOT E, ZWINDERMAN A et al.: Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia. Arch. Intern. Med. (2003) 163:1837-1841.
71. CORTI R, BADIMON J: Value or desirable of hemorheological-hemostatic parameter changes asendpoints in blood lipid-regulatin trials. Curr. Opin. Lipidol. (2001) 12:629-637
72. TAKEMOTO M, LIAO J: Pleiotropic effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors. Arterioscler. Thromb. Vasc. Biol. (2001) 21:1712-1719.
73. SIMONS LA, SULLIVAN D, SIOMONS J et al.: Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endotelial function in patients with severe primary hipercolesterolemia. Atherosclerosis (1998) 137:197-203.
74. YOKOYAMA I, YONEKURA K, INOUE Y et al.: Long-term effect of simvastatin on the improvement of impaired myocardial flow reserve in patients with familial hypercholesterolemia without gender variance. J. Nucl. Cardiol. (2001) 8:445-451.
75. GIRONA J, LA VILLE AE, SOLA R et al.: Simvastatin decreases aldehyde production derived from liporptoein oxidation. Am. J. Cardiol. (1999) 83:846-851
76. TOMAS M, SENTI M, GARCIA-FARIA F et al.: Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. (2000) 20:2113-2119
77. DEMUTH K, MYARA I, CHAPPEY B et al.: A cytotoxic electronegative LDL subfraction is present in human plasma. Arterioscler. Thromb. Vasc. Biol. (1996) 16:773-783.
78. BENITEZ S, ORDOÑEZ-LLANOS J, FRANCO M et al.: Effect of simvastatin in familial hipercolesterolemia on the affinity of electronegative low-density lipoprotein subfraction to the low-density lipoprotein receptor. Am. J. Cardiol. (2004) 93:414-420.
79. SANCHEZ-QUESADA J, OTAL-ENTRAIGAS C, FRANCO M et al.: Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Am. Cardiol. (1999) 84:665-659
80. FERRO D, BASILI S, ALESSANDRI C et al.: Simvastatin reduces monocyte-tissue-factor expression in Type IIa hypercholesterolaemia. Lancet (1997) 350:12-22.
81. REZAIE-MAJD A, MACA T, BUCEK R et al.: Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocyte from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. (2002) 22:1194-1199
82. RAUCH U, OSENDE JI, CHESEBRO JH et al.: Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis (2000) 153:181-189.
83. CORTI R, FUSTER V, FAYAD ZA et al.: Lipid-lowering by simvastatin induces regression of human atherosclerotic lesions: 2 year follow-up by high-resolution noninvasive MRI. Circulation (2002) 106:2884-2887.
84. BOCCUZZI SJ, KEEGAN ME, HIRSCH LJ et al.: Long-term experience with simvastatin. Drug Invest. (1993) 5:135-140.
85. STAFFA JA, CHANG J, GREEN L: Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. (2002) 346:539-540.
86. LIJNEN P, CELIS H, FAGARD R et al.: Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems. J. Hypertens. (1994) 12:59-64.
87. LAAKSONEN R, JOKELAINEN K, SAHI T et al.: Decrease in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin. Parmacol. Ther. (1995) 57:62-66.
88. EVANS M, REES A: The myotocicity of statins. Curr. Opin. Lipidol. (2002) 13:415-420.
89. UCAR M, MJÖRNDAL T, DAHLQVIST R: HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. (2000) 22:441-457.
90. EVANS M, REES A: Effects of HMG-CoA reductase inhibitors on skeletal muscle. Are all statins the same?. Drug Saf. (2002) 25:649-663
91. PASTERNAK R, SMITH S, BAIREY-MERZ CN et al.: ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Circulation (2002) 106:1024-1028.
92. GOLDMAN L, GOLDMAN PA, WILLIAMS LW et al.: Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am. J. Cardiol. (1993) 72:75D-79D.
93. JOHANNESSON M, JONSONN B, KJEKSHUS J et al.: Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N. Engl. J. Med. (1997) 336:332-336
94. WORLD HEALTH ORGANISATION, Human Genetics Program, Division of Non-communicable diseases: Familial Hypercholesterolemia, report of a WHO consultation. WHO/HGN/FH/CONS/98.7. Paris, October 1997.
95. DURRINGTON P: The human and economic costs of undertreatment with statins. Int. J. Clin. Pract. (2002) 56:357-368.